A Dose-Escalating Study of Weekly Bolus Topotecan in Previously Treated Ovarian Cancer Patients

Objective. Topotecan is an established topoisomerase I inhibitor for the treatment of relapsed ovarian cancer. Myelotoxicity and suboptimal patient convenience associated with daily topotecan, however, have prompted investigators to explore alternate regimens, including a weekly regimen of topotecan...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2001-11, Vol.83 (2), p.394-399
Hauptverfasser:	Homesley, Howard D., Hall, Don J., Martin, David A., Lewandowski, George S., Vaccarello, Luis, Nahhas, William A., Suggs, Charles L., Penley, Rebecca G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences cancer antigen 125 Chemotherapy dose escalation dose-limiting tolerability Dose-Response Relationship, Drug Drug Administration Schedule Enzyme Inhibitors - adverse effects Enzyme Inhibitors - therapeutic use Female Humans Medical sciences Middle Aged myelotoxicity ovarian cancer Ovarian Neoplasms - drug therapy Pharmacology. Drug treatments topoisomerase I topotecan Topotecan - adverse effects Topotecan - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!